Associate Scientist III, Metabolic Diseases
- South San Francisco, CA
- Full-time
- $120,349-$129,000/yr
- Posted
Skills
Job description
Associate Scientist III, Metabolic Diseases, wanted by Insitro, Inc. in South San Francisco, CA. Engineer complex 3D cell models (spheroids and co-cultures) using various cell types for mechanistic studies; Develop and qualify workflows to validate drug targets, define mechanism of action and conduct pharmacology studies for drug discovery using techniques such as CRISPR, siRNA and RNAseq; Independently develop and optimize in vitro assays by leveraging molecular biology techniques, advanced microscopy and automated instrumentation for metabolic disease phenotyping; Generate datasets from ex vivo samples for key efficacy and target engagement readouts to enable critical go/no-go decisions; Analyze high-throughput datasets using sophisticated Machine Learning-based pipelines; Lead small projects end-to-end and coordinate handoffs between multi-disciplinary teams to meet key project milestones; Generate presentations and publication material for effective scientific communication at the company level; Adhere to good lab practices and document all experimental parameters meticulously in an Electronic Lab Notebook (ELN) for data integrity.
Must have a Master’s degree in Biotechnology, Bioengineering or a related field plus two (2) years of experience in a related occupation. In lieu of a Master’s degree plus two (2) years of experience, we will accept a Bachelor’s degree in Biotechnology, Bioengineering or a related field plus five (5) years of progressive experience in a related occupation. Must have two (2) years of experience handling primary, immortalized, and iPSC-derived cell lines (such as hepatocytes, fibroblasts and endothelial cells) and engineering complex disease models including co-cultures and spheroids; two (2) years of experience executing high throughput screening such as pooled optical, arrayed CRISPR screens and siRNA drug discovery screens; two (2) years of experience handling tool compounds such as oligonucleotides, small molecules and antibodies for functional validation, disease phenotyping, and mechanistic studies; two (2) years of experience applying molecular biology techniques for gene expression such as qPCR and RNAseq; and protein expression such as Jess, MSD, and Luminex; two (2) years of experience developing pharmacology and drug discovery assays, and establishing qualification metrics (Z’, % CV, IC50 and reproducibility); two (2) years of experience leveraging advanced microscopy, high-content imaging, and analysis using Machine Learning-based image segmentation pipelines; two (2) years of experience with large-scale processing of ex-vivo tissues (liver, fat or pancreas) for downstream assays; two (2) years of experience handling state of the art automation instrumentation such as Agilent Bravo, Hamilton STAR, ECHO and Multidrop combi; two (2) years of experience with using LIMS and other lab oriented software such as GraphPad Prism (data analysis) and Benchling (Electronic Lab Notebook)
$120,349-$129,000/yr. Please send resume to: ta-resumes@insitro.com and refer to: Job Req._2026-insitro-005P____.
insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.
We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.
#LI-Hybrid
Please be aware of recruitment scams: we never request payments, all recruitment communications are from @insitro.com http://insitro.com, and if in doubt, contact us at info@insitro.com.
About insitro
insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com http://www.insitro.com.